He was diagnosed with stage IV lung adenocarcinoma (Fig 1a) in April 2019 when epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) genomic aberrations were determined not to be present, but he was found to have a high PD‐L1 expression of 60% (Fig 1b). This evidence concerns the gene ALK and lung adenocarcinoma.